## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.86 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Caution: declining volume (50% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($59.67)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. DexCom, Inc. Sued for Securities Law Violations â€“ Investors**
- Source: GlobeNewswire | 20251201T211800 | Neutral | Relevance: 99%
- Levi & Korsinsky, LLP has filed a class action securities lawsuit against DexCom, Inc. (NASDAQ: DXCM) alleging securities fraud. The lawsuit claims that DexCom made material design changes to its G6 and G7 glucose monitoring products without FDA authorization, rendering them less reliable and posing health risks, and that the company made false and misleading statements. Investors who suffered losses between January 8, 2024, and September 17, 2025, have until December 26, 2025, to seek appointment as lead plaintiff.

**2. Investors SueWallSt Over DexCom, Inc. Stock Drop - Contact Levi & Korsinsky to Join**
- Source: WTRF | 20251202T173000 | Neutral | Relevance: 99%
- A class action lawsuit has been filed against DexCom, Inc. on behalf of investors who experienced losses due to alleged securities fraud between January 8, 2024, and September 17, 2025. Levi & Korsinsky, LLP is encouraging affected investors to contact them to join the lawsuit. The firm specializes in securities litigation and has a strong track record of securing funds for aggrieved shareholders.

**3. Investors SueWallSt Over DexCom, Inc. Stock Drop - Contact Levi & Korsinsky to Join**
- Source: WANE 15 | 20251202T223000 | Neutral | Relevance: 99%
- A class action lawsuit has been filed against DexCom, Inc. on behalf of investors who experienced financial losses due to alleged securities fraud between January 8, 2024, and September 17, 2025. Investors who suffered losses are encouraged to contact Levi & Korsinsky to join the lawsuit. Levi & Korsinsky is a law firm with a strong track record in securities litigation, having secured hundreds of millions for aggrieved shareholders.

**4. DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!**
- Source: WRIC ABC 8News | 20251202T120000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made false and misleading statements regarding unauthorized material design changes to its G6 and G7 devices, which compromised their reliability and presented health risks to users. Investors with substantial losses are encouraged to apply to be a lead plaintiff by December 26, 2025.

**5. DexCom, Inc. Class Action: The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025 - DXCM**
- Source: Morningstar | 20251201T134500 | Neutral | Relevance: 99%
-  The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. (NASDAQ: DXCM) regarding a pending class action lawsuit. The lawsuit alleges that DexCom made material design changes to its glucose monitoring products (G6 and G7) without FDA authorization, rendering them less reliable and posing health risks. Investors who purchased shares between January 8, 2024, and September 17, 2025, are encouraged to contact the firm, with a lead plaintiff deadline of December 26, 2025.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 14.5% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (1 raises, avg +19%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.5B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 25.9 |
| Current P/E | 31.2 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 3.2% to 5.7% (+2.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 92nd percentile. MRS_5 at 1.4% confirms short-term momentum alignment. AM_20 at 7.5% shows strong absolute momentum above own 20MA. Outperforming sector by 5.9pp, stock-specific strength. Below SMA200 (0.85x), long-term trend not supportive. MACD histogram positive (0.96), confirming momentum. RSI neutral at 56. Volume at 50% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.67% (CS: 93) | Strong |
| RSI_14 | 56.4 | Neutral |
| MACD Histogram | 0.96 | Bullish |
| vs SMA20 | 1.075x | Above |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 0.855x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $64.45
- **Stop Loss:** $59.67 (7.4% risk)
- **Target:** $74.01 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 209
- **Position Value:** $13,470.05
- **Portfolio %:** 13.47%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*